Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn's disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study

被引：0
|
作者：
Sands, B. E. [1 ]
Colombel, J. F. [1 ]
Rubin, D. T. [2 ]
Schreiber, S. [3 ]
Siegel, C. A. [4 ]
Yarur, A. [5 ]
Danese, S. [6 ,7 ]
Kang, A. [8 ]
Kim, D. H. [8 ]
Lee, Y. N. [8 ]
Hanauer, S. B. [9 ]
机构：
[1] Dr Henry D Janowitz Div Gastroenterol, Icahn Sch Med Mt Sinai, New York, NY USA
[2] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[3] Univ Hosp Schleswig Holstein, Dept Med 1, Kiel, Germany
[4] Dartmouth Hitchcock Inflammatory Bowel Dis Ctr, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA
[5] F Widjaja Inflammatory Bowel Dis Inst, Cedars Sinai Med Ctr, Angeles, CA USA
[6] IRCCS San Raffaele Hosp, Milan, Italy
[7] Univ Vita Salute San Raffaele, Dept Gastroenterol, Milan, Italy
[8] Celltr Inc, Global Med Div, Incheon, South Korea
[9] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0812
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0638
引用
收藏
页码：I1254 / I1256
页数：2
相关论文
共 50 条
  • [21] SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY
    Danese, Silvio
    Colombel, Jean-Frederic
    Hanauer, Stephen
    Sandborn, William
    Sands, Bruce
    Schreiber, Stefan
    Lee, Sang Joon
    Kim, Sung Hyun
    Bae, Yun Ju
    Lee, Sun Hee
    Lee, Seul Gi
    Lee, Joon Ho
    Kim, Jong Min
    Yang, Si Young
    Lee, Jimin
    Park, Ga Hee
    Lee, Ju Hyun
    GASTROENTEROLOGY, 2024, 166 (03) : S13 - S13
  • [22] SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY
    Danese, Silvio
    Colombel, Jean-Frederic
    Hanauer, Stephen
    Sandborn, William
    Sands, Bruce
    Schreiber, Stefan
    Lee, Sang Joon
    Kim, Sung Hyun
    Bae, Yun Ju
    Lee, Sun Hee
    Lee, Seul Gi
    Lee, Joon Ho
    Kim, Jong Min
    Yang, Si Young
    Lee, Jimin
    Park, Ga Hee
    Lee, Ju Hyun
    INFLAMMATORY BOWEL DISEASES, 2024, 30
  • [23] Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study
    Papaioannou, Andriana
    Kallieri, Maria
    Zervas, Eleftherios
    Fouka, Evangelia
    Porpodis, Konstaninos
    Hadjimitrova, Marija
    Tzortzaki, Eleni
    Makris, Michael
    Ntakoula, Maria
    Lyberopoulos, Panagiotis
    Dimakou, Katerina
    Koukidou, Sofia
    Ampelioti, Sevasti
    Papaporfyriou, Anastasia
    Katsoulis, Konstantinos
    Kipourou, Maria
    Rovina, Nikoletta
    Antoniou, Katerina
    Vittorakis, Stylianos
    Bakakos, Petros
    Steiropoulos, Paschalis
    Markopoulou, Katerina
    Avarlis, Panteleimon
    Papanikolaou, lias
    Markatos, Miltiadis
    Gaki, Eleni
    Samitas, Konstantinos
    Glynos, Konstantinos
    Papiris, Spyros
    Papakosta, Despoina
    Tzanakis, Nikolaos
    Gaga, Mina
    Kostikas, Konstantinos
    Loukides, Stelios
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [24] THE VISIBLE 2 PHASE 3 STUDY OF EFFICACY AND SAFETY OF VEDOLIZUMAB SC FOR MODERATE-TO-SEVERE CROHN'S DISEASE
    Vermeire, Severine
    D'Haens, Geert R.
    Baert, Filip J.
    Danese, Silvio
    Kobayashi, Taku
    Loftus, Edward V.
    Bhatia, Siddharth
    Kisfalvi, Krisztina
    Rosario, Maria
    Zhang, Wenwen
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 158 (06) : S194 - S194
  • [25] RISANKIZUMAB MAINTENANCE THERAPY RESULTS IN SUSTAINED IMPROVEMENTS IN ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: POST-HOC ANALYSIS FROM THE PHASE 3 STUDY FORTIFY
    Irving, Peter M.
    Abreu, Maria T.
    Axler, Jeffrey
    Gao, Xiang
    Torres, Joana
    Neimark, Ezequiel
    Song, Alexandra P.
    Wallace, Kori
    Kligys, Kristina
    Berg, Sofie
    Liao, Xiaomei
    Panaccione, Remo
    GASTROENTEROLOGY, 2022, 162 (07) : S975 - S975
  • [26] Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn's Disease: Post-hoc analysis from the phase 3 study FORTIFY
    Irving, P. M.
    Abreu, M.
    Axler, J.
    Gao, X.
    Torres, J.
    Neimark, E.
    Song, A.
    Wallace, K.
    Kligys, K.
    Berg, S.
    Liao, X.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I127 - I128
  • [27] Faecal calprotectin combined with faecal lactoferrin in predicting the endoscopic outcomes of patients with moderate-to-severe Crohn's disease receiving infliximab: a pilot study
    Wu, J.
    Huang, W.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S470 - S471
  • [28] HIGHER POST-INDUCTION INFLIXIMAB CONCENTRATIONS ARE ASSOCIATED WITH FAVORABLE CLINICAL OUTCOMES IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE REACH STUDY
    Papamichail, Konstantinos
    Vande Casteele, Niels
    Wang, Zhongya
    Dubinsky, Marla C.
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2022, 162 (07) : S804 - S804
  • [29] Reduction of Fecal Calprotectin and Clinical Symptoms in the Phase 2 Study of Laquinimod for the Treatment of Active Moderate-to-Severe Crohn's Disease
    D'Haens, Geert R.
    Sandborn, William
    Colombel, Jean-Frederic
    Brown, Kurt
    Haviv, Asi
    Barkay, Hadas
    Sakov, Anat
    Feagan, Brian G.
    GASTROENTEROLOGY, 2014, 146 (05) : S368 - S369
  • [30] RAPID SYMPTOMATIC IMPROVEMENT WITH SUBCUTANEOUS INFLIXIMAB INDUCTION TREATMENT FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: FIRST RESULTS FROM THE DIRECT-CD STUDY
    Anjie, Suzanne I.
    Jharap, Bindia
    Jansen, Jeroen M.
    Mares, Wout
    Duijvestein, Marjolijn
    Maljaars, Jeroen
    Oldenburg, Bas
    D'Haens, Geert
    Gecse, Krisztina
    GASTROENTEROLOGY, 2024, 166 (05) : S510 - S510
12345